If you have been reading about gastric juice protein and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-12-11. Numbers and descriptions here follow the published literature rather than marketing material.
Terminology in the literature is not fully standardised. Papers and product listings use BPC-157, BPC 157, and the longer phrase stable gastric pentadecapeptide BPC 157 interchangeably, and synonyms such as bepecin or PL 14736 appear in older or company-linked publications. Purity claims and reported masses can also differ between sources because peptide preparations may include counterions, residual solvents, or bound water. This variability complicates direct comparison of results across studies and makes the exact identity and grade of a given sample worth verifying. Discussions of the compound should therefore specify the source, salt form, and stated purity where those are known.
BPC-157 is a synthetic peptide composed of fifteen amino acid residues, with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. Its name derives from body protection compound, a term used for a protein fraction identified in human gastric juice. Researchers in Zagreb first reported the pentadecapeptide in the early 1990s and described it as a stable fragment of that larger protein. The compound is also catalogued as PL 14736 and, in some commercial contexts, as bepecin. Its molecular formula is C62H98N16O22 and its monoisotopic mass is approximately 1419 daltons.
Most early work on this peptide originated in the 1990s from a research group in Zagreb, Croatia, relying on animal models and cell cultures. Reported observations included effects on gastrointestinal lesion healing, tendon fibroblast migration, and blood vessel formation under controlled laboratory conditions. These findings come predominantly from rodent studies and in vitro assays rather than from human trials. Controlled human data remain limited, and the degree to which animal results translate to human physiology is an open question rather than a settled fact.
Within the research literature, the peptide is discussed through several provisional mechanisms, including cytoprotection, modulation of growth factor signaling, and interaction with the nitric oxide system. None of these mechanisms is fully characterized, and no single pathway is universally accepted. Review articles typically note the gap between consistent animal findings and sparse human evidence. The compound is classified as a research chemical rather than an approved pharmaceutical, which shapes how studies are designed, funded, and reported.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C62H98N16O22 | Computed for the free peptide |
| Monoisotopic mass | Approximately 1419 Da | Reported values shift with counterion and hydration |
| Residue count | 15 amino acids | Sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val |
| Origin | Fragment of human gastric juice protein | First described in early 1990s research reports |
| Common synonyms | BPC 157; PL 14736; bepecin | Naming varies across papers and catalogues |
Confirmation of identity and purity relies on standard peptide analysis techniques. Reverse-phase high-performance liquid chromatography separates the peptide from related impurities and serves as the most common purity assay. Mass spectrometry, often coupled to that chromatography step, provides an accurate molecular mass that can be matched against the expected value. Amino acid analysis or sequencing can be added for further confirmation. Because short peptides can be produced by different synthetic routes, laboratories usually report both a chromatographic purity percentage and a mass confirmation rather than a single figure.
BPC-157 is commonly supplied as a lyophilized powder, a freeze-dried solid that is reconstituted before use in laboratory work. As a short peptide, it dissolves readily in water and in aqueous buffer solutions, and stock solutions are typically prepared in water or a mild buffer. The chain contains several proline and acidic residues, which influence how it behaves in solution. Because the solid can take up moisture, weighing and handling are usually performed under low-humidity conditions. Its solubility class is described as freely soluble in water rather than requiring an organic solvent.
The sequence contains an unusually high proportion of proline and glycine, which limits regular secondary structure and contributes to solubility in aqueous media. The compound dissolves readily in water and in normal saline. Because it is a peptide, digestive enzymes are expected to break it down if it is swallowed, a consideration that influences the routes of administration used in animal experiments. Detailed conformational data remain limited, and published structural models are largely computational.
BPC 157 is a synthetic peptide built from fifteen amino acids. The letters stand for body protection compound, and the number is a laboratory code rather than a description of any biological feature. Its single-letter sequence is GEPPPGKPADDAGLV, which corresponds to a calculated mass near 1419.5 daltons. The material is produced by solid-phase peptide synthesis and is distributed as a lyophilized powder, not as a purified extract from a natural source.
Published storage guidance follows general peptide practice rather than product-specific studies. The dry powder is typically kept at minus 20 degrees Celsius, away from light and moisture. Once reconstituted, solutions are generally refrigerated and used over days to weeks, because the aqueous environment slowly promotes hydrolysis and oxidation. Long-term data on degradation rates or breakdown products are sparse. Stated shelf lives from different producers vary widely, reflecting the absence of a shared reference standard.
BPC-157 is a synthetic peptide built from fifteen amino acid residues. Its sequence comes from a larger protein fragment that researchers isolated from human gastric juice and described as a body protection compound. The fragment contains glycine, glutamic acid, five prolines, lysine, alanine, two aspartic acids, leucine, and valine. The number 157 in the name refers to the position of the stretch within the parent protein. Material used in laboratories is manufactured rather than extracted from stomach fluid.
The molecule carries 15 residues, a molar mass near 1419.5 g/mol, and the formula C62H98N16O22. Its structure features a proline-rich central region, a pair of adjacent aspartic acid residues, and no cysteine. The absence of cysteine means no disulfide bonds can form, which simplifies refolding and reconstitution. Suppliers usually ship the material as a freeze-dried powder that appears white to off-white. It dissolves readily in water and in saline solutions.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography, often paired with mass spectrometry using electrospray or MALDI ionisation. Amino acid analysis and peptide mapping by enzymatic digestion provide additional sequence-level confirmation. Purity is commonly reported as an area percentage from a chromatographic trace, and water content can be measured by Karl Fischer titration. Reported masses may differ by tens of daltons between sources because preparations can contain acetate or trifluoroacetate counterions, and such differences are not by themselves evidence of a different peptide.
BPC-157 is normally distributed as a lyophilised powder that ranges from white to off-white in appearance. The peptide dissolves readily in water, normal saline, and common aqueous buffers, and it is poorly soluble in nonpolar solvents such as hexane or vegetable oils. Lyophilised vials take up moisture if left open, which changes the mass of powder in the container and complicates any later weighing. Because the material is handled in small quantities, static and adhesion to glass or plastic can also cause noticeable losses during transfer.
The main chemical liabilities of this sequence are peptide-bond hydrolysis and possible aspartate-related reactions, since the peptide contains aspartic acid residues but no cysteine, methionine, or tryptophan. Absence of those three residues removes the most common oxidation and disulfide pathways from consideration. Studies of related peptides indicate that aspartate isomerisation and aspartimide formation occur most readily at Asp-Gly and Asp-Ala positions, and open questions remain about how quickly those reactions proceed under ordinary laboratory conditions. Storage guidance typically emphasises cool, dry, dark conditions to slow hydrolysis.
== Assistants == Nurse aide (CNA) Nurse technician (CNT) Care partner (CP) Medical Assistants Certified Medical Assistant (CMA) Certified Medical Assistant - Admin (CMA-A) Certified Medical Assistant - Clinical (CMA-C) Certified Medical Assistant - Admin and Clinical (CMA-AC) Registered Medical Assistant (RMA) Medical Assistant (MA) Certified Clinical Medical Assistant (CCMA) Certified Medical Administrative Assistant (CMAA) Pharmacy Technician Certified Pharmacy Technician (CPhT)
For example, the stepwise liquid-phase synthesis of the dipeptide Z-L-Phg-L-Val-OMe yields the LL-product with 81-84% which is free from racemic DL dipeptide, using From N-protected Z-L-α-phenylglycine (with the benzyloxycarbonyl group, Z group) and L-valine methyl ester with the coupling reagent DIC and the additive ethyl cyanohydroxyiminoacetate. More recently, a variety of derivatives of ethyl cyanohydroxyiminoacetate (Oxyma) have been developed as acylation reagents, such as Fmoc-oxyma for the transfer of the fluorenylmethoxycarbonyl protective group
As the number of known specimens increased, scientists began to analyze the variation between individuals and discovered what appeared to be two distinct body types, or morphs, similar to some other theropod species. As one of these morphs was more solidly built, it was termed the 'robust' morph while the other was termed 'gracile'. Several morphological differences associated with the two morphs were used to analyze sexual dimorphism in T. rex, with the 'robust' morph usually suggested to be female. For example, the pelvis of several 'robust' specimens seemed to be wider, perhaps to allow the passage of eggs. It was also thought that the 'robust' morphology correlated with a reduced chevron on the first tail vertebra, also ostensibly to allow eggs to pass out of the reproductive tract, as had been erroneously reported for crocodiles. In recent years, evidence for sexual dimorphism has been weakened. A 2005 study reported that previous claims of sexual dimorphism in crocodile chevron anatomy were in error, casting doubt on the existence of similar dimorphism between T. rex sexes. A full-sized chevron was discovered on the first tail vertebra of Sue, an extremely robust individual, indicating that this feature could not be used to differentiate the two morphs anyway. As T. rex specimens have been found from Saskatchewan to New Mexico, differences between individuals may be indicative of geographic variation rather than sexual dimorphism. The differences could also be age-related, with 'robust' individuals being older animals.
== Further reading == "Comparison of Joint Commission and Healthcare Facilities Accreditation Program (HFAP) Emergency-Related Standards for Hospitals" (PDF). American Health Lawyers Association. Barabas, MC (Sep 2002). "Healthcare facilities accreditation program: the recognized alternative to the joint commission on accreditation of healthcare organizations". JONA's Healthcare Law, Ethics, and Regulation. 4 (3): 48–9. doi:10.1097/00128488-200209000-00002. PMID 12352575.
Sources: en.wikipedia.org
== Early life == Pickston was born in Oldham, Lancashire, and grew up in Shaw, Lancashire, where she was raised by her grandfather, William Fawcett. Her father, Paul Fawcett, worked for British Telecom during her early years. Pickston attended Rishworth School. Her mother, whose surname is Yachan, is Thai.
=== 2010s === In 2010, Grace received approval from the U.S. Bankruptcy Court for the merger with Synthetec, which is a company that had developed and manufactured amino acid and peptide products as well as proprietary custom chiral intermediates primarily for the pharmaceutical industry. In 2014, the Grace bankruptcy process terminated. However, some legal procedures continued into the next decade. In February 2016, Grace completed the corporate spin-off of GCP Applied Technologies, which was also as a public trading corporation on the NYSE. Grace shareholders receive GCP stock on 1:1 ratio. GCP Applied Technologies consisted of the concrete admixture and related products company Grace Construction Products (GCP) and Darex, a packaging technologies business unit. In July 2016, Grace acquired the global polyolefin catalysts business unit from BASF.
22 January – ScotRail announces another suspension of train services from 7pm the following day ahead of the arrival of Storm Jocelyn. 23 January – The Rail Accident Investigation Branch launches an investigation into a collision between a train and a fallen tree at 84 mph (135 kmh) at Broughty Ferry on the Dundee–Aberdeen line during Storm Gerrit in December 2023. 26 January – French Holocaust denier Vincent Reynouard, who spent two years on the run in Scotland before being apprehended by police in November 2022, loses his appeal against extradition to France, where he faces charges of inciting hatred and denying the occurrence of the Holocaust. 28 January – The Met Office records a provisional peak temperature of 19.6 °C (67.3 °F) at Kinlochewe in the Scottish Highlands, setting a new record for January temperatures in the area. 29 January – Edinburgh City Council implements a ban on pavement parking. Engineers begin four days of work to install netting above the railway at Ratho to prevent potential rockfall, causing disruption to Central Belt railway services while the work is carried out. Robert O'Brian and Andrew Kelly are to appeal against their sentences for the murder of Caroline Glachan. 31 January – The Scottish Government confirms it will introduce a ban on the sale and exchange of American XL bully dogs from 23 February, while a licence to own one will be required from 31 July.
Carrey reunited with Joel Schumacher, director of Batman Forever, for The Number 23 (2007), a psychological thriller co-starring Virginia Madsen and Danny Huston. In the film, Carrey plays a man who becomes obsessed with the number 23, after finding a book about a man with the same obsession. The film was panned by critics. The following year Carrey provided his voice for Dr. Seuss' Horton Hears a Who! (2008). Carrey voiced Horton the Elephant for the CGI-animated feature, which was a box office success, grossing over $290 million worldwide. Carrey returned to live-action comedy, starring opposite Zooey Deschanel and Bradley Cooper in Yes Man (also 2008). Carrey played a man who signs up for a self-help program that teaches him to say yes to everything. Despite reviews being mixed, Rene Rodriquez of The Miami Herald stated, "Yes Man is fine as far as Jim Carrey comedies go, but it's even better as a love story that just happens to make you laugh." The film earned $225 million at the box office worldwide.
== Medical application == S. helianthus shows a variety of promising applications in the medical field due to its toxin-producing capability. ShK-186, a peptide inhibitor, is a toxin that has been previously implemented in clinical trials for its potential treatment of autoimmune diseases. It has been further developed into an “investigational drug”, known as Dalazatide, in which it targets the disease-causing cells corresponding to ailments including type 1 diabetes, lupus erythematosus and multiple sclerosis. The aforementioned cytolysins, St I and St II, have also shown pharmacological potential in studies with guinea pig models, with direct implications on neural and cardiac activity. Due to its capability of protease inhibition, ShPI-1 is another toxin with medical potential. This toxin is a “non-specific inhibitor” and provides a variant with “increased biomedical potential” for its inhibition properties. Though many of these toxins require further research, S. helianthus serves great potential in biomedical applications for toxin production.
Sources: en.wikipedia.org
BPC-157 is a synthetic fifteen-amino-acid peptide whose sequence corresponds to a fragment of a protein found in human gastric juice. It is studied mainly in preclinical research and is not an approved pharmaceutical product in major markets. Materials sold for laboratory use are typically labelled as research chemicals.
No medicines regulator in the United States or the European Union has approved BPC-157 as a therapeutic product. Presenting it as a drug or as a dietary supplement ingredient would generally not match its regulatory status. Availability as a research chemical does not imply clinical approval.
Published reports rest largely on animal models and cell culture rather than controlled human trials. Review articles describe the proposed mechanisms as incompletely understood. Conclusions about effects in humans therefore remain tentative.
The sequence corresponds to a fragment of a protein found in human gastric juice, so related sequences are natural. The isolated fifteen-amino-acid peptide supplied for research is produced synthetically. Whether the free fragment circulates naturally in humans has not been settled.